6.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
What institutional flow reveals about Capricor Therapeutics Inc.July 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Historical volatility pattern of Capricor Therapeutics Inc. visualizedJuly 2025 Breakouts & Consistent Profit Focused Trading Strategies - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a good hedge against inflationJuly 2025 Sentiment & Weekly Breakout Stock Alerts - newser.com
Can trapped investors hope for a rebound in Capricor Therapeutics Inc.Weekly Risk Summary & Precise Buy Zone Tips - newser.com
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
How Capricor Therapeutics Inc. stock reacts to job market dataQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
How analysts rate Capricor Therapeutics Inc. stock todayJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Heatmap analysis for Capricor Therapeutics Inc. and competitors2025 Price Momentum & Community Verified Trade Alerts - newser.com
Capricor Therapeutics : Investor PresentationOctober 2025 - MarketScreener
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR): Evaluating Valuation After Lawsuit and FDA Decision Shake Investor Confidence - Yahoo Finance
Capricor Therapeutics (CAPR): Assessing Valuation After FDA Setback and Class Action Complaint - Sahm
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 170% Upside Potential in Biotechnology - DirectorsTalk Interviews
Is a relief rally coming for Capricor Therapeutics Inc. holdersWeekly Risk Summary & Daily Profit Focused Screening - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is FDA Embrace of HOPE-3 Data Shaping the Investment Thesis for Capricor Therapeutics (CAPR)? - Sahm
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025Weekly Loss Report & Community Driven Trade Alerts - newser.com
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Capricor Therapeutics Inc Stock Analysis and ForecastMomentum Stock Picks & Minimal Investment Capital Gains - earlytimes.in
What drives Capricor Therapeutics Inc 4LN2 stock priceMarket Correction Analysis & Affordable Market Insights - earlytimes.in
Will Capricor Therapeutics Inc. stock see PE expansionInsider Buying & Free Verified High Yield Trade Plans - newser.com
Volume spikes in Capricor Therapeutics Inc. stock – what they meanWeekly Market Report & Daily Technical Forecast Reports - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock profit from AI boom2025 Market Overview & Growth Focused Investment Plans - newser.com
Is Capricor Therapeutics Inc. stock resilient to inflationJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval - streetwisereports.com
Capricor Therapeutics Inc. recovery potential after sell off2025 Sector Review & Safe Entry Zone Tips - newser.com
Published on: 2025-10-05 04:39:29 - newser.com
User - FinancialContent
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewswire
There's Reason For Concern Over Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Massive 26% Price Jump - 富途牛牛
Head to Head Review: Baxter International (NYSE:BAX) and Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Largest borrow rate increases among liquid names - TipRanks
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy - streetwisereports.com
Biotech Battles FDA, Target Price Shows Potential 90% Gains - streetwisereports.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):